Lowest Price Guaranteed
Pages
238
Last Updated
July 2026
View Count
18656
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Precision Medicine
3.2.1. Evolution of Precision Medicine
3.2.2. Novel Approaches in Precision Medicine
3.2.2.1. Biomarkers and Decision Making
3.2.2.2. Genomics, Epigenetics and MicroRNAs as Emerging Biomarkers
3.2.2.3 Biomarker Multiplexing
3.2.2.4. Digital Biomarkers
3.2.2.5. Metabolomics
3.3. Key Technology Platforms
3.3.1. Cloud Based
3.3.2. On-Premises
3.4. Key Challenges Faced by Precision Medicine Software Developers
3.4.1. Unprecedented Data Volumes
3.4.2. Interpreting Data Deluge at the Level of Individual
3.4.3. Incorporation into the Clinic
3.5. Application Areas
3.6. Benefits of Precision Medicine over Traditional Treatment Modalities
3.6.1. Benefits to Patients
3.6.2. Benefits to Healthcare Providers
3.7. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Precision Medicine Software Developers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Region
4.2.4. Analysis by Status of Development
4.2.5. Analysis by Type of Platform
4.2.6. Analysis by Regulatory Accreditations
4.2.5. Analysis by Purpose of Software
4.2.6. Analysis by Type of Data Handled
4.2.7. Analysis by Therapeutic Area
4.2.8. Analysis by Type of End-User
4.3. Most Active Players: Analysis by Number of Software
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Precision Medicine Software Developers
5.2.1. AceTech
5.2.1.1. Company overview
5.2.1.2. Product portfolio
5.2.1.3. Recent Developments and Future Outlook
5.2.2. Ariel Precision Medicine
5.2.2.1. Company Overview
5.2.2.2. Product Portfolio
5.2.2.3. Recent Developments and Future Outlook
5.2.3. C2i Genomics
5.2.3.1. Company Overview
5.2.3.2. Product Portfolio
5.2.3.3. Recent Developments and Future Outlook
5.2.4. Genedata
5.2.4.1. Company Overview
5.2.4.2. Product Portfolio
5.2.4.3. Recent Developments and Future Outlook
5.2.5. Inspirata
5.2.5.1. Company Overview
5.2.5.2. Product Portfolio
5.2.5.3. Recent Developments and Future Outlook
5.2.6. IQVIA
5.2.6.1. Company Overview
5.2.6.2. Product Portfolio
5.2.6.3. Recent Developments and Future Outlook
5.3. Additional Profiles
5.3.1. Fabric Genomics
5.3.1.1. Company Overview
5.3.1.2. Product Portfolio
5.3.1.3. Recent Developments and Future Outlook
5.3.2. GenomOncology
5.3.2.1. Company Overview
5.3.2.2. Product Portfolio
5.3.2.3. Recent Developments and Future Outlook
5.3.3. Human Longevity
5.3.3.1. Company Overview
5.3.3.2. Product Portfolio
5.3.3.3. Recent Developments and Future Outlook
5.3.4. SOPHiA GENETICS
5.3.4.1. Company Overview
5.3.4.2. Product Portfolio
5.3.4.3. Recent Developments and Future Outlook
5.3.5. Syapse
5.3.5.1. Company Overview
5.3.5.2. Product Portfolio
5.3.5.3. Recent Developments and Future Outlook
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Company Competitiveness Analysis Based on Company size
6.2.1. Assumptions / Key Parameters
6.2.2. Methodology
6.2.3. Company Competitiveness Analysis: Small Companies
6.2.4. Company Competitiveness Analysis: Mid-sized Companies
6.2.5. Company Competitiveness Analysis: Large and Very Large Companies
6.3. Company Competitiveness Analysis Based on Geographical Region
6.3.1. Assumptions / Key Parameters
6.3.2. Methodology
6.3.3. Company Competitiveness Analysis: Companies in North America
6.3.4. Company Competitiveness Analysis: Companies in Europe, Asia-Pacific and Rest of the World
6.4. Key Players Based on Proprietary Scores
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Precision Medicine Software Developers: Patent Analysis
7.3.1. Analysis by Type of Patent
7.3.2. Analysis by Publication Year
7.3.3. Analysis by Publication Year and Type of Patent
7.3.4. Analysis by Geography
7.3.4.1. Patent Analysis: North America Scenario
7.3.4.2. Patent Analysis: Europe Scenario
7.3.4.3. Patent Analysis: Asia-Pacific Scenario
7.3.5. Analysis by CPC Symbols
7.3.6. Analysis by Emerging Focus Area
7.3.7. Most Active Players: Analysis by Number of Patents
7.3.8. Most Active Inventors: Analysis by Number of Patents
7.3.9. Analysis by Type of Organization
7.3.10. Patent Benchmarking Analysis
7.3.10.1. Analysis by Patent Characteristics
7.3.10.1.1. Tempus Labs and GenomSys
7.3.10.1.2. Other Leading Patent Assignees
7.3.11. Patent Valuation Analysis
7.3.12. Legal Status Analysis
7.3.12.1. Analysis by Legal Status
7.3.12.2. Analysis by Geography and Legal Status
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Precision Medicine Software Developers: List of Partnerships
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Year of Partnership and Focus Area
8.3.6. Analysis by Type of Partnership and Focus Area
8.3.7. Analysis by Therapeutic Area
8.3.8. Analysis by Type of Partnership and Type of Platform
8.3.9. Analysis by Type of Partnership and Type of Data Handled
8.3.10. Analysis by Region
8.3.10.1. Continent-wise Distribution
8.3.10.2. Intercontinental and Intracontinental Distribution
8.3.10.3. Country-wise Distribution
8.3.11. Most Active Players: Analysis by Number of Partnerships
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Precision Medicine Software Developers: Funding and Investment Analysis
9.3.1 Analysis by Number of Funding Instances by Year
9.3.2. Analysis of Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Regional Analysis by Amount Invested
9.3.5. Analysis by Year and Type of Funding
9.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
9.3.7. Key Investors: Analysis by Number of Instances
9.3.8. Analysis by Purpose of Investment
9.3.9. Analysis by Type of Data Handled
9.3.10. Analysis by Therapeutic Area
10. ATTRACTIVENESS COMPETETIVENESS MATRIX
10.1. Chapter Overview
10.2. AC Matrix: Overview
10.2.1. Strong Business Segments
10.2.2. Average Business Segments
10.2.3. Weak Business Segments
10.3. AC Matrix: Analytical Methodology
10.4. AC Matrix: Precision Medicine Software Developers for Different Therapeutic Areas
10.5. AC Matrix: Precision Medicine Software Developers in Different Regions
11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Assumptions
11.3. Global Precision Medicine Software Developers Market, 2021-2032
11.3.1. Precision Medicine Software Developers Market, 2021-2032: Analysis by Therapeutic Area
11.3.1.1. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2032
11.3.1.2. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2032
11.3.1.3. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2032
11.3.1.4. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2032
11.3.1.5. Precision Medicine Software Developers Market for Other Disorders, 2021-2032
11.3.2. Precision Medicine Software Developers Market, 2021-2032: Analysis by Type of End-User
11.3.2.1. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2032
11.3.2.2. Precision Medicine Software Developers Market for Hospitals, 2021-2032
11.3.3. Precision Medicine Software Developers Market, 2021-2032: Analysis by Region
11.3.3.1. Precision Medicine Software Developers Market in North America, 2021-2032
11.3.3.2. Precision Medicine Software Developers Market in Europe, 2021-2032
11.3.3.3. Precision Medicine Software Developers Market in Asia-Pacific and Rest of the World, 2021-2032
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors
12.7. Concluding Remarks
13. CONCLUDING REMARKS
13.1. Chapter Overview
14. APPENDIX I: TABULATED DATA
15. APPENDIX II: LIST OF COMPANIES
Figure 2.1. Executive Summary: Developer Landscape
Figure 2.2. Executive Summary: Partnerships and Collaborations
Figure 2.3. Executive Summary: Funding and Investments
Figure 2.4. Executive Summary: Patent Analysis
Figure 2.5. Executive Summary: Market Forecast
Figure 3.1. Evolution of Precision Medicine
Figure 3.2. Applications of Precision Medicine
Figure 4.1. Precision Medicine Software Developers: Distribution by Year of Establishment
Figure 4.2. Precision Medicine Software Developers: Distribution by Company Size
Figure 4.3. Precision Medicine Software Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4. Precision Medicine Software Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5. Precision Medicine Software Developers: Distribution by Company Size and Region
Figure 4.6. Precision Medicine Software Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 4.7. Precision Medicine Software Applications: Distribution by Status of Development
Figure 4.8. Precision Medicine Software Applications: Distribution by Status of Development and Region
Figure 4.9. Precision Medicine Software Applications: Distribution by Type of Platform
Figure 4.10. Precision Medicine Software Applications: Distribution by Regulatory Accreditation Received
Figure 4.11. Precision Medicine Software Applications: Distribution by Purpose of Software Applications
Figure 4.12. Precision Medicine Software Applications: Distribution by Type of Data Handled
Figure 4.13. Precision Medicine Software Applications: Distribution by Status of Development and Type of Data Handled
Figure 4.14. Precision Medicine Software Applications: Distribution by Therapeutic Area
Figure 4.15. Precision Medicine Software Applications: Distribution by Therapeutic Area and Status of Development
Figure 4.16. Precision Medicine Software Applications: Distribution by Type of Data Handled and Therapeutic Area
Figure 4.17. Precision Medicine Software Applications: Distribution by Type of End-User
Figure 4.18. Most Active Players: Distribution by Number of Software Applications
Figure 6.1. Company Competitiveness Analysis: Small Companies Scenario
Figure 6.2. Company Competitiveness Analysis: Mid-sized Companies Scenario
Figure 6.3. Company Competitiveness Analysis: Large and Very Large Companies Scenario
Figure 6.4. Company Competitiveness Analysis: Companies in North America
Figure 6.5. Company Competitiveness Analysis: Companies in Europe, Asia-Pacific and Rest of the World
Figure 6.6. Key Players Based on Proprietary Scores
Figure 7.1. Patent Analysis: Distribution by Type of Patent
Figure 7.2. Patent Analysis: Distribution by Publication Year, 2018-2021
Figure 7.3. Patent Analysis: Distribution of Granted Patents by Publication Year
Figure 7.4. Patent Analysis: Distribution by Geography (Continent-wise)
Figure 7.5. Patent Analysis: North America Scenario (Region-wise)
Figure 7.6. Patent Analysis: Europe Scenario (Region-wise)
Figure 7.7. Patent Analysis: Asia-Pacific Scenario (Region-wise)
Figure 7.8. Patent Analysis: Distribution by CPC Classification
Figure 7.9. Patent Analysis: Distribution by Emerging Focus Area
Figure 7.10. Most Active Players: Distribution by Number of Patents
Figure 7.11. Most Active Inventors: Distribution by Number of Patents
Figure 7.12. Overall Intellectual Property Portfolio: Distribution by Type of Organization
Figure 7.13. Patent Benchmarking Analysis: Tempus Labs and GenomSys
Figure 7.14. Patent Benchmarking Analysis: Other Leading Players
Figure 7.15. Patent Analysis: Distribution by Patent Age
Figure 7.16. Patent Analysis: Patent Relative Valuation
Figure 7.17. Patent Analysis: Distribution by Legal Status
Figure 7.18. Patent Analysis: Distribution by Legal Status and Geography
Figure 8.1. Partnerships: Distribution by Year of Partnership
Figure 8.2. Partnerships: Distribution by Type of Partnership
Figure 8.3. Partnerships: Distribution by Year and Type of Partnership
Figure 8.4. Partnerships: Distribution by Focus Area
Figure 8.5. Heat Map: Distribution by Year of Partnership and Focus Area
Figure 8.6. Partnerships: Distribution by Type of Partnership and Focus Area
Figure 8.7. Partnerships: Distribution by Therapeutic Area
Figure 8.8. Partnerships: Distribution by Type of Partnership and Type of Platform
Figure 8.9. Partnerships: Distribution by Type of Partnership and Type of Data Handled
Figure 8.10. Partnerships: Continent-wise Distribution
Figure 8.11. Partnerships: Intercontinental and Intracontinental Agreements
Figure 8.12. Partnerships: Country-wise Distribution
Figure 8.13. Most Active Players: Distribution by Number of Partnerships
Figure 9.1. Funding and Investment Analysis: Distribution by Year of Funding (2018-2021)
Figure 9.2. Funding and Investment Analysis: Distribution of Amount Invested by Year (USD Million)
Figure 9.3. Funding and Investment Analysis: Distribution Type of Funding, 2018-2021
Figure 9.4. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2018-2021 (USD Million)
Figure 9.5. Funding and Investment Analysis: Summary of Investments, 2018-2020 (USD Million)
Figure 9.6. Funding and Investment Analysis: Distribution by Geography
Figure 9.7. Funding and Investment Analysis: Distribution of Instances by Geography 2018-2020
Figure 9.8. Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2018-2021
Figure 9.9. Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, 2018-2021 (USD Million)
Figure 9.10. Most Active Players: Distribution by Number of Funding Instances
Figure 9.11. Most Active Investors: Distribution by Amount Raise (USD Million)
Figure 9.12. Funding and Investment Analysis: Distribution by Type of Investor
Figure 9.13. Funding and Investment Analysis: Distribution by Purpose of Investment
Figure 9.14. Funding and Investment Analysis: Distribution by Type of Data Handled
Figure 9.15. Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 10.1. AC Matrix: Pictorial Representation
Figure 10.2. AC Matrix: Precision Medicine Software Developers for Various Therapeutic Areas
Figure 10.3. AC Matrix: Precision Medicine Software Developers in Regions
Figure 11.1. Global Precision Medicine Software Developers Market, 2021-2032 (USD Million)
Figure 11.2. Precision Medicine Software Developers Market: Distribution by Therapeutic Area, 2022 and 2032
Figure 11.3. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2032 (USD Million)
Figure 11.4. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2032 (USD Million)
Figure 11.5. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2032 (USD Million)
Figure 11.6. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2032 (USD Million)
Figure 11.7. Precision Medicine Software Developers Market for Other Disorders, 2021-2032 (USD Million)
Figure 11.8. Precision Medicine Software Developers Market: Distribution by Types of End-users, 2022 and 2032 (USD Million)
Figure 11.9. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2032 (USD Million)
Figure 11.10. Precision Medicine Software Developers Market for Hospitals, 2021-2032 (USD Million)
Figure 11.11. Precision Medicine Software Developers Market: Distribution by Geography, 2022 and 2032 (USD Million)
Figure 11.12. Precision Medicine Software Developers Market in North America, 2021-2032 (USD Million)
Figure 11.13. Precision Medicine Software Developers Market in Europe, 2021-2032 (USD Million)
Figure 11.14. Precision Medicine Software Developers Market in Asia-Pacific and Rest of the World, 2021-2032 (USD Million)
Figure 12.1. Precision Medicine Software Developers: SWOT Analysis
Figure 12.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1. Concluding Remarks: Current Market Landscape
Figure 13.2. Concluding Remarks: Patent Analysis
Figure 13.3. Concluding Remarks: Partnerships and Collaborations
Figure 13.4. Concluding Remarks: Funding and Investment Analysis
Figure 13.5. Concluding Remarks: Market Sizing and Opportunity Analysis
Table 4.1. Precision Medicine Software Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 4.2. Precision Medicine Software Applications: Information on Software Applications, Status of Development, and Compliance
Table 4.3. Precision Medicine Software Applications: Information on Therapeutic Area, Type of Data Handled, Purpose of Software and Type of End-User
Table 5.1. AceTech: Company Overview
Table 5.2. AceTech: Product Portfolio
Table 5.3. Ariel Precision Medicine: Company Overview
Table 5.4. Ariel Precision Medicine: Product Portfolio
Table 5.5. Ariel Precision Medicine: Recent Developments and Future Outlook
Table 5.6. C2i Genomics: Company Overview
Table 5.7. C2i Genomics: Product Portfolio
Table 5.8. C2i Genomics: Recent Developments and Future Outlook
Table 5.9. Genedata: Company Overview
Table 5.10. Genedata: Product Portfolio
Table 5.11. Genedata: Recent Developments and Future Outlook
Table 5.12. Inspirata: Company Overview
Table 5.13. Inspirata: Product Portfolio
Table 5.14. IQVIA: Company Overview
Table 5.15. IQVIA: Product Portfolio
Table 5.16. IQVIA: Recent Developments and Future Outlook
Table 5.17. Fabric Genomics: Company Overview
Table 5.18. Fabric Genomics: Product Portfolio
Table 5.19. GenomOncology: Company Overview
Table 5.20. GenomOncology: Product Portfolio
Table 5.21. Human Longevity: Company Overview
Table 5.22. Human Longevity: Product Portfolio
Table 5.23. SOPHiA GENETICS: Company Overview
Table 5.24. SOPHiA GENETICS: Product Portfolio
Table 5.25. SOPHiA GENETICS: Recent Developments and Future Outlook
Table 5.26. Syapse: Company Overview
Table 5.27. Syapse: Product Portfolio
Table 5.28. Syapse: Recent Developments and Future Outlook
Table 7.1. Patent Analysis: List of Top CPC Symbols
Table 7.2. Patent Analysis: Summary of Benchmarking Analysis
Table 7.3. Patent Analysis: Various Categorization based on Weighted Scores
Table 7.4. Patent Analysis: List of Leading Patents (in terms of highest relative valuation)
Table 8.1. Partnerships and Collaborations: List of Partnerships
Table 8.2. Partnerships and Collaborations: Information on Focus Area, Therapeutic Area, Type of Platform and Type of Data Handled
Table 9.1. Precision Medicine Software Developers Market: Funding and Investments, 2018-2021
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 9.3 Funding and Investment Analysis: Summary of Venture Capital Round
Table 9.4 Fundings and Investments: Information on Purpose of Investment, Type of Data Handled and Therapeutic Area
Table 14.1. Precision Medicine Software Developers: Distribution by Year of Establishment
Table 14.2. Precision Medicine Software Developers: Distribution by Company Size
Table 14.3. Precision Medicine Software Developers: Distribution by Location of Headquarters (Region-wise)
Table 14.4. Precision Medicine Software Developers: Distribution by Location of Headquarters (Country-wise)
Table 14.5. Precision Medicine Software Developers: Distribution by Company Size and Region
Table 14.6. Precision Medicine Software Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 14.7. Precision Medicine Software Applications: Distribution by Status of Development
Table 14.8. Precision Medicine Software Applications: Distribution by Status of Development and Region
Table 14.9. Precision Medicine Software Applications: Distribution by Type of Platform
Table 14.10. Precision Medicine Software Applications: Distribution by Regulatory Accreditations Received
Table 14.11. Precision Medicine Software Applications: Distribution by Type of Data Handled
Table 14.12. Precision Medicine Software Applications: Distribution by Status of Development and Type of Data Handled
Table 14.13. Precision Medicine Software Applications: Distribution by Therapeutic Area
Table 14.14. Precision Medicine Software Applications: Distribution by Therapeutic Area and Status of Development
Table 14.15. Precision Medicine Software Applications: Distribution by Type of Data Handled and Therapeutic Area
Table 14.16. Precision Medicine Software Developers: Distribution by Type of End-User
Table 14.17. Most Active Players: Distribution by Number of Software Applications
Table 14.18. Patent Analysis: Distribution by Type of Patent
Table 14.19. Patent Analysis: Distribution by Publication Year, 2018-2021
Table 14.20. Patent Analysis: Distribution of Granted Patents by Publication Year
Table 14.21. Patent Analysis: Distribution by Geography (Continent-wise)
Table 14.22. Patent Analysis: North America Scenario (Region-wise)
Table 14.23. Patent Analysis: Europe Scenario (Region-wise)
Table 14.24. Patent Analysis: Asia-Pacific Scenario (Region-wise)
Table 14.25. Most Active Players: Distribution by Number of Patents
Table 14.26. Most Active Inventors: Distribution by Number of Patents
Table 14.27. Overall Intellectual Property Portfolio: Distribution by Type of Organization
Table 14.28. Patent Analysis: Distribution by Patent Age
Table 14.29. Patent Analysis: Patent Relative Valuation
Table 14.30. Patent Analysis: Distribution by Legal Status
Table 14.31. Patent Analysis: Distribution by Legal Status and Geography
Table 14.32. Partnerships: Distribution by Year of Partnership
Table 14.33. Partnerships: Distribution by Type of Partnership
Table 14.34. Partnerships: Distribution by Year and Type of Partnership
Table 14.35. Partnerships: Distribution by Focus Area
Table 14.36. Partnerships: Distribution by Year of Partnership and Focus Area
Table 14.37. Partnerships: Distribution by Type of Partnership and Focus Area
Table 14.38. Partnerships: Distribution by Therapeutic Area
Table 14.39. Partnerships: Country-wise Distribution
Table 14.40. Most Active Players: Distribution by Number of Partnerships
Table 14.41. Funding and Investment Analysis: Distribution by Year of Funding (2018-2021)
Table 14.42. Funding and Investment Analysis: Distribution of Amount Invested by Year (USD Million)
Table 14.43. Funding and Investment Analysis: Distribution of Type of Funding, 2018-2021
Table 14.44. Funding and Investment Analysis: Distribution of Amount Invested by the Type of Funding, 2018-2021 (USD Million)
Table 14.45. Funding and Investment Analysis: Summary of Investments, 2018-2020 (USD Million)
Table 14.46. Funding and Investment Analysis: Distribution by Geography
Table 14.47. Funding and Investment Analysis: Distribution of Instances by Geography 2018-2020
Table 14.48. Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2018-2021
Table 14.49. Funding and Investment Analysis: Distribution of Instances by Year, Type of Funding and Amount Invested, 2018-2021 (USD Million)
Table 14.50. Most Active Players: Distribution by Number of Funding Instances
Table 14.51. Most Active Investors: Distribution by Amount Raise (USD Million)
Table 14.52. Funding and Investment Analysis: Distribution by Type of Investor
Table 14.53. Funding and Investment Analysis: Distribution by Purpose of Investment
Table 14.54. Funding and Investment Analysis: Distribution by Type of Data Handled
Table 14.55. Funding and Investment Analysis: Distribution by Therapeutic Area
Table 14.56. Global Precision Medicine Software Developers Market, 2021-2032 (USD Million)
Table 14.57. Precision Medicine Software Developers Market: Distribution by Therapeutic Area, 2022 and 2032
Table 14.58. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2032 (USD Million)
Table 14.59. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2032 (USD Million)
Table 14.60. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2032 (USD Million)
Table 14.61. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2032 (USD Million)
Table 14.62. Precision Medicine Software Developers Market for Other Disorders, 2021-2032 (USD Million)
Table 14.63. Precision Medicine Software Developers Market: Distribution by Types of End-users, 2022 and 2032 (USD Million)
Table 14.64. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2032 (USD Million)
Table 14.65. Precision Medicine Software Developers Market for Hospitals, 2021-2032 (USD Million)
Table 14.66. Precision Medicine Software Developers Market: Distribution by Geography, 2022 and 2032 (USD Million)
Table 14.67. Precision Medicine Software Developers Market in North America, 2021-2032 (USD Million)
Table 14.68. Precision Medicine Software Developers Market in Europe, 2021-2032 (USD Million)
Table 14.69. Precision Medicine Software Developers Market in Asia-Pacific and Rest of the World , 2021-2032 (USD Million)
Please reach out to our team for the details.